Vertex Pharmaceuticals Incorporated (ETR: VX1)
Germany
· Delayed Price · Currency is EUR 377.20
+3.55 (0.95%)
Dec 20, 2024, 5:35 PM CET
Vertex Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Operating Revenue | 10,626 | 9,869 | 8,931 | 7,573 | 6,203 | 4,161 | Upgrade
|
| Other Revenue | - | - | - | 1 | 2.9 | 2.1 | Upgrade
|
| Revenue | 10,626 | 9,869 | 8,931 | 7,574 | 6,206 | 4,163 | Upgrade
|
| Revenue Growth (YoY) | 10.06% | 10.51% | 17.91% | 22.06% | 49.08% | 36.59% | Upgrade
|
| Cost of Revenue | 4,931 | 4,425 | 3,608 | 2,842 | 2,381 | 2,302 | Upgrade
|
| Gross Profit | 5,695 | 5,444 | 5,323 | 4,732 | 3,825 | 1,861 | Upgrade
|
| Selling, General & Admin | 1,456 | 1,137 | 944.7 | 840.1 | 770.5 | 658.5 | Upgrade
|
| Operating Expenses | 1,456 | 1,137 | 944.7 | 840.1 | 770.5 | 658.5 | Upgrade
|
| Operating Income | 4,239 | 4,308 | 4,378 | 3,892 | 3,054 | 1,202 | Upgrade
|
| Interest Expense | -38.4 | -44.1 | -54.8 | -61.5 | -58.2 | -58.5 | Upgrade
|
| Interest & Investment Income | 649.4 | 614.7 | 144.6 | 4.9 | 22.2 | 63.7 | Upgrade
|
| Currency Exchange Gain (Loss) | -22.5 | -24.6 | -15.1 | -13.9 | -16.1 | -5.2 | Upgrade
|
| Other Non Operating Income (Expenses) | -45.5 | 9.3 | -0.6 | 1.7 | 0.8 | -0.2 | Upgrade
|
| EBT Excluding Unusual Items | 4,782 | 4,863 | 4,453 | 3,824 | 3,003 | 1,202 | Upgrade
|
| Gain (Loss) on Sale of Investments | -13 | -7.5 | -149.1 | 17.1 | 311.9 | 197.6 | Upgrade
|
| Asset Writedown | - | - | -13 | - | - | - | Upgrade
|
| Other Unusual Items | 49.6 | 51.6 | 57.5 | 3.1 | -13.1 | -4.5 | Upgrade
|
| Pretax Income | 259.6 | 4,380 | 4,232 | 2,730 | 3,117 | 1,395 | Upgrade
|
| Income Tax Expense | 739.4 | 760.2 | 910.4 | 388.3 | 405.2 | 218.1 | Upgrade
|
| Earnings From Continuing Operations | -479.8 | 3,620 | 3,322 | 2,342 | 2,712 | 1,177 | Upgrade
|
| Net Income to Company | -479.8 | 3,620 | 3,322 | 2,342 | 2,712 | 1,177 | Upgrade
|
| Net Income | -479.8 | 3,620 | 3,322 | 2,342 | 2,712 | 1,177 | Upgrade
|
| Net Income to Common | -479.8 | 3,620 | 3,322 | 2,342 | 2,712 | 1,177 | Upgrade
|
| Net Income Growth | - | 8.96% | 41.84% | -13.63% | 130.43% | -43.88% | Upgrade
|
| Shares Outstanding (Basic) | 258 | 258 | 256 | 258 | 260 | 257 | Upgrade
|
| Shares Outstanding (Diluted) | 258 | 261 | 259 | 260 | 263 | 261 | Upgrade
|
| Shares Change (YoY) | -0.91% | 0.54% | -0.31% | -1.33% | 1.04% | 0.58% | Upgrade
|
| EPS (Basic) | -1.86 | 14.05 | 12.97 | 9.09 | 10.44 | 4.58 | Upgrade
|
| EPS (Diluted) | -1.86 | 13.89 | 12.82 | 9.01 | 10.29 | 4.51 | Upgrade
|
| EPS Growth | - | 8.35% | 42.29% | -12.44% | 128.16% | -44.24% | Upgrade
|
| Free Cash Flow | -1,106 | 3,337 | 3,925 | 2,409 | 2,994 | 1,494 | Upgrade
|
| Free Cash Flow Per Share | -4.29 | 12.81 | 15.15 | 9.27 | 11.37 | 5.73 | Upgrade
|
| Gross Margin | 53.59% | 55.16% | 59.60% | 62.48% | 61.63% | 44.69% | Upgrade
|
| Operating Margin | 39.89% | 43.65% | 49.03% | 51.39% | 49.21% | 28.87% | Upgrade
|
| Profit Margin | -4.52% | 36.68% | 37.20% | 30.92% | 43.70% | 28.27% | Upgrade
|
| Free Cash Flow Margin | -10.41% | 33.81% | 43.95% | 31.80% | 48.24% | 35.89% | Upgrade
|
| EBITDA | 4,447 | 4,477 | 4,527 | 4,018 | 3,164 | 1,309 | Upgrade
|
| EBITDA Margin | 41.85% | 45.36% | 50.69% | 53.05% | 50.98% | 31.44% | Upgrade
|
| D&A For EBITDA | 207.9 | 169.5 | 148.3 | 125.6 | 109.5 | 106.9 | Upgrade
|
| EBIT | 4,239 | 4,308 | 4,378 | 3,892 | 3,054 | 1,202 | Upgrade
|
| EBIT Margin | 39.89% | 43.65% | 49.03% | 51.39% | 49.21% | 28.87% | Upgrade
|
| Effective Tax Rate | 284.82% | 17.36% | 21.51% | 14.22% | 13.00% | 15.64% | Upgrade
|
| Revenue as Reported | 9,869 | 9,869 | 8,931 | 7,574 | 6,206 | 4,163 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.